Vericel Corp Ord - Asset Resilience Ratio
Vericel Corp Ord (VCEL) has an Asset Resilience Ratio of 7.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Vericel Corp Ord strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2025)
This chart shows how Vericel Corp Ord's Asset Resilience Ratio has changed over time. See VCEL equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Vericel Corp Ord's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Vericel Corp Ord market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $37.41 Million | 7.67% |
| Total Liquid Assets | $37.41 Million | 7.67% |
Asset Resilience Insights
- Limited Liquidity: Vericel Corp Ord maintains only 7.67% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vericel Corp Ord Industry Peers by Asset Resilience Ratio
Compare Vericel Corp Ord's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Vericel Corp Ord (1997–2025)
The table below shows the annual Asset Resilience Ratio data for Vericel Corp Ord.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.67% | $37.41 Million | $487.97 Million | -1.97pp |
| 2024-12-31 | 9.64% | $41.69 Million | $432.72 Million | -1.81pp |
| 2023-12-31 | 11.44% | $40.47 Million | $353.66 Million | -13.64pp |
| 2022-12-31 | 25.08% | $68.47 Million | $273.00 Million | +10.69pp |
| 2021-12-31 | 14.39% | $35.07 Million | $243.71 Million | -6.13pp |
| 2020-12-31 | 20.52% | $42.19 Million | $205.61 Million | -7.43pp |
| 2019-12-31 | 27.95% | $42.83 Million | $153.24 Million | -26.51pp |
| 2018-12-31 | 54.46% | $64.64 Million | $118.69 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $54.58 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $48.60 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $34.31 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $47.58 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $9.21 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $15.18 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $7.74 Million | -- |
| 2010-12-31 | 15.23% | $5.00 Million | $32.83 Million | -10.71pp |
| 2009-12-31 | 25.94% | $5.00 Million | $19.28 Million | +3.17pp |
| 2008-12-31 | 22.77% | $5.97 Million | $26.22 Million | -22.55pp |
| 2007-12-31 | 45.32% | $14.89 Million | $32.85 Million | -30.36pp |
| 2006-12-31 | 75.67% | $33.96 Million | $44.88 Million | +22.55pp |
| 2005-12-31 | 53.12% | $18.01 Million | $33.90 Million | -46.00pp |
| 2004-12-31 | 99.12% | $18.01 Million | $18.17 Million | +90.46pp |
| 2002-12-31 | 8.66% | $1.00 Million | $11.55 Million | +0.26pp |
| 2001-12-31 | 8.40% | $1.00 Million | $11.90 Million | -71.09pp |
| 2000-12-31 | 79.49% | $10.68 Million | $13.44 Million | +5.67pp |
| 1998-12-31 | 73.82% | $9.13 Million | $12.37 Million | -14.70pp |
| 1997-12-31 | 88.52% | $18.51 Million | $20.91 Million | -- |
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more